Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | LATS1 | O95835 | 1/20 | 0.30 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179269 | 0.81 | CYP19A1 (0.46) | CYP19A1HSP90AA1CYP3A4KIF11P2RX7 | |
| SCHEMBL21101453 | 0.78 | CYP19A1 (0.38) | CYP19A1HSP90AA1CYP3A4LATS1LATS2 | |
| SCHEMBL27886405 | 0.77 | CYP19A1 (0.47) | CYP19A1HSP90AA1CYP3A4KIF11P2RX7 | |
| SCHEMBL31691964 | 0.77 | CYP19A1 (0.43) | CYP19A1HSP90AA1CYP3A4KIF11P2RX7 | |
| SCHEMBL16091462 | 0.77 | CYP19A1 (0.52) | CYP19A1HSP90AA1CYP3A4KIF11P2RX7 | |
| SCHEMBL16454356 | 0.77 | CYP19A1 (0.43) | CYP19A1HSP90AA1CYP3A4KIF11P2RX7 | |
| SCHEMBL16454702 | 0.77 | CYP19A1 (0.43) | CYP19A1HSP90AA1CYP3A4KIF11P2RX7 | |
| SCHEMBL4879351 | 0.76 | CYP19A1 (0.42) | CYP19A1HSP90AA1CYP3A4KIF11CYP2D6 | |
| SCHEMBL24137127 | 0.74 | CYP19A1 (0.41) | CYP19A1HSP90AA1CYP3A4KIF11 | |
| SCHEMBL16677128 | 0.74 | CYP19A1 (0.41) | CYP19A1HSP90AA1CYP3A4P2RX7KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129389-B2 | Substituted oxindole derivatives, medicaments containing the latter and use thereof | ABBOTT GMBH & CO. KG (DE) | 2012-03-06 | — | — | US | disclosed |
| US-8129389-B2 | Substituted oxindole derivatives, medicaments containing the latter and use thereof | ABBOTT GMBH & CO. KG (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20090186904-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | ABBOTT GMBH & CO. KG | 2009-07-23 | — | — | US | disclosed |
| US-20090186904-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | ABBOTT GMBH & CO. KG | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186904-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | OXTR, AVPR2, AVPR1B | CYP19A1 362/4885HSP90AA1 1676/4885CYP3A4 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.